alkylating agents:
	- cyclophosphamide
	- ifosfamide

platinums:
	- cisplatin
	- carboplatin
	- oxaliplatin

antimetabolites:
	- 5-fluorouracil (5FU) / capecitabine (oral)
	- methotrexate
	- gemcitabine

anti-microtubules:
	- paclitaxel / docetaxel (taxanes)
	- vincristine

topoisomerase I inhibitors:
	- irinotecan
	- topotecan

topoisomerase II inhibitors: 
	- etoposide

anthracyclines: 
	- doxorubicin

anti-tumor antibiotics: 
	- bleomycin



HER2 targeted:
	- trastuzumab
	- pertuzumab

EGFR/EGF targeted:
	- cetuximab

VEGF targeted:
	- bevacizumab

HER2 targeted:
	- Ado-trastuzumab emtansine (T-DM1)
	- fam-trastuzumab deruxtecan (T-Dxd)

Trop-2 targeted:
	- sacituzimab govitecan



checkpoint inhibitors:
	- pembrolizumab / nivolumab (PD-1)
	- atezolizumab (PD-1L)
	- ipilimumab (CTLA-4)



selective estrogen receptor modulator (SERM):
	- tamoxifen

aromatase inhibitors:
	- anastrazole, letrozole, exemestane

GnRH agonists:
	- leuprolide, goserelin, buserelin, triptorelin

anti-androgen:
	- bicalutamide
	- enzulatamide

androgen synthesis inhibitors:
	- abiraterone



kinase inhibitors:
	- ribociclib, palbociclib, abemaciclib

EGFR tyrosine kinase inhibitors:
	- erlotinib, gefitinib, afatinib, osimertinib

ALK + RET tyrosine kinase inhibitors:
	- alectinib

BRAF kinase inhibitors:
	- debrafinib, vemurafinib

MEK kinase inhibitors:
	- tremetinib, cobimetinib

Bcr-Abl + cKIT tyrosine kinase inhibitors:
	- imatinib

poly ADP-ribose polymerase inhibitors (PARPi):
	- olaparib

multiple receptor tyrosine kinase inhibitors:
	- sunitinib
	- pazopanib


therapeutic cancer vaccines:
	- sipuleucel-T

radiopharmaceutical:
	- radium 223


osteoclast inhibitors:
	- bisphosphonates (zoledronic acid)
	- denosumab